Webinar: Selectivity Profiling: Unbiased Analysis of Compound Selectivity in Drug Discovery by InsideScientific

Already registered?

Selectivity Profiling: Unbiased Analysis of Compound Selectivity in Drug Discovery

About

Join us for an in-depth webinar exploring how CETSA® Selectivity Profiling empowers smarter decision-making in drug discovery.

Laurence Arnold from Pelago Bioscience presents case studies demonstrating the impact of the service across diverse targets, modalities, and stages of discovery.

The service offers an unbiased, proteome-wide view of compound interactions accessing biologically relevant targets that conventional selectivity panels often miss.

Powered by automated sample preparation and high-throughput LC/MS proteomics, the service enables analysis of approximately 100 samples/day with quantification of >5,000 proteins in lysate. As a result, you obtain actionable insights within 10 working days, accelerating the DMTA cycle and supporting data-driven lead optimization

Live Q&A: Bring your questions and explore how CETSA Selectivity can be seamlessly integrated into your discovery programs.

All intellectual property rights, including copyrights and trademarks, relating to CETSA are owned by Pelago Bioscience AB.

WEBINAR ENDED

Presenters

Laurence Arnold, PhD

Head of R&D, Pelago Bioscience

Laurence Arnold is the Head of R&D at Pelago Bioscience. With a background in Protein biochemistry and Biophysics he and his team leverage CETSA data to determine actionable insights from cellular drug:protein interactions alongside developing the next generation of products stemming from target engagement.

Tove Boström, PhD

Product Manager, Pelago Bioscience

Tove Boström is a Product Manager at Pelago Bioscience, contributing to the development of CETSA-based solutions for drug discovery. With a strong background in proteomics and mass spectrometry, she supports the growing proteomics offering and helps turn customer needs into practical, effective applications.